Expecting what, when?, page-77

Also for 2018 I have the following:
Turkey and Spain coming online in Q1 (assume no official ASX announcement due to being part of Europe)
Lodging of China clinical registration trial (this is an important step in the process towards gaining approval which is expected late 2019-2020 with first sales 2020)
South Africa Q3
Australia TGA and possibly separately 3D, Q3 and with that South East Asia follows (I believe these to be Taiwan, Vietnam, Thaliand, Philippines)
India 3D sometime in 2018
Jordan, Iraq, Iran, Bahrain and Oman sometime in 2018
Of the countries we are already approved for Cardiocel in I expect approvals for 3D this year as per recent Canada announcement, those being New Zealand, Singapore, Malaysia, Hong Kong in addition to the MENA and Europe 3D you have mentioned
I expect an update on Japan which was under review (Japan is a very lucrative market for pharma, and I assume medtech, as they are willing to pay a premium for quality products) however the approval process is long in Japan
With countries we are yet to gain approval as per above I'm not clear if 3D is bundled in to the approval process or if that's separate. History seems to suggest we can expect a Cardiocel approval initially followed by a 3D approval later on.
I hope this helps, Chris